Learn more

NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECHNOLOGY CO LTD

Overview
  • Total Patents
    60
  • GoodIP Patent Rank
    24,395
About

NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECHNOLOGY CO LTD has a total of 60 patent applications. Its first patent ever was published in 2015. It filed its patents most often in China. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and environmental technology are STABILIMENTI CHIMICO FARMACEUT, NANJING HAIAOSI BIOLOGICAL MEDICINE TECH CO LTD and NANJING FUHAIAOSAI PHARMACEUTICAL CO LTD.

Patent filings in countries

World map showing NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECHNOLOGY CO LTDs patent filings in countries
# Country Total Patents
#1 China 60

Patent filings per year

Chart showing NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECHNOLOGY CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Lu Xian 58
#2 Jiang Chunping 12
#3 Wu Junhua 2

Latest patents

Publication Filing date Title
CN106727464A The derivative composition of Harrisotone A is used to prevent and treat hepar damnification
CN106822073A The derivative composition of Harrisotone A is used for anti-chronic obstructive pulmonary disease
CN106822074A The derivative composition of Harrisotone A is used for anti-inflammatory
CN106667980A Application of composition of derivatives of Harrisotone A in resisting acute gout
CN106727463A The derivative composition of Harrisotone A is used for anti-osteoporosis
CN106727596A Harrisotone A morpholinyls and 1H tetrazole radical derivatives composition are used to prevent and treat hepar damnification
CN106822144A Harrisotone A morpholinyls and 1H tetrazole radical derivatives composition are used for anti-acute gout
CN106822145A Harrisotone A morpholinyls and 1H tetrazole radical derivatives composition are used for anti-inflammatory
CN106822143A Harrisotone A morpholinyls and 1H tetrazole radical derivatives composition are used for anti-osteoporosis
CN106822146A Harrisotone A morpholinyls and 1H tetrazole radical derivatives composition are used for anti-chronic obstructive pulmonary disease
CN106491573A Application of the compositionss of O (lignocaine) ethyl derivatives and O (piperazinyl) ethyl derivative of Harrisotone A in the low property anemia medicine of anti-erythrocyte
CN106491605A Application of the compositionss of O (lignocaine) ethyl derivatives and O (piperazinyl) ethyl derivative of Harrisotone A in anti-hepatic fibrosis medicines
CN106491608A The application of Harrisotone A lignocaines and Piperazino derivs composition in antiviral drugs
CN106491610A Application of the compositionss of O (lignocaine) ethyl derivatives and O (piperazinyl) ethyl derivative of Harrisotone A in preventing and treating hepar damnification medicine
CN106420752A Application of Harrisotone A derivative composition in medicine for treating or preventing renal fibrosis
CN106420682A Application of harrisotone A diethylamino and piperazinyl derivative composition to medicines for resisting acute gout
CN106580990A Application of Harrisotone A derivative compositions in anti-inflammatory drugs
CN106491609A The application of Harrisotone A lignocaines and Piperazino derivs compositionss in anti-acute renal failure medicine
CN106420748A Application of Harrisotone A lignocaine and piperazine-based derivative composition in medicine for raising white blood cells
CN106491606A The application of Harrisotone A lignocaines and Piperazino derivs composition in anti-chronic obstructive pulmonary disease